Lifetime opiate exposure as an independent and interactive cardiovascular risk factor in males: A cross-sectional clinical study

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 551-561

  Reece, Albert S ^a   Hulse, Gary K ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Arterial stiffness; Heroin; Human aging; Methadone; Opiate dependence; Vascular aging

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BUPRENORPHINE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; DIAMORPHINE; GLOBULIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METHADONE; NALTREXONE; TRIACYLGLYCEROL; UREA;

ADULT; AGE; AGING; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; CARDIOVASCULAR AGING; CARDIOVASCULAR RISK; CENTRAL VENOUS PRESSURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DOSE RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; HEART PERFUSION; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE EJECTION TIME; HUMAN; LIFESPAN; LONG TERM EXPOSURE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OPIATE ADDICTION; PREDICTIVE VALUE; PULSE RATE; PULSE WAVE; RISK FACTOR; SENESCENCE; SMOKING; SUBSTANCE ABUSE; TREATMENT DURATION; VASCULAR AGE;

ARTERIAL STIFFNESS; HEROIN; HUMAN AGING; METHADONE; OPIATE DEPENDENCE; VASCULAR AGING;

ADULT; AGE FACTORS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMICS; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OPIATE SUBSTITUTION TREATMENT; PULSE WAVE ANALYSIS; RISK FACTORS; SEX FACTORS; TIME FACTORS; VASCULAR STIFFNESS; YOUNG ADULT;

EID: 84889862173     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S48030     Document Type: Article

References (43)

1. Gottshcalk LA, McGuire FL, Heiser JF, Dinovo EC, Birch H. Drug Abuse Deaths In Nine Cities: A Survey Report. Rockville: National Institute of Drug Abuse; 1979.
2. Cami J, Farre M. Drug addiction. N Engl J Med. 2003;349(10): 975-986.
3. Darke S, Degenhardt L, Mattick R. Mortality Amongst Illicit Drug Users: Epidemiology, Causes And Intervention. Sydney: Cambridge University Press; 2006.
4. Darke S, Duflou J, Torok M. The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend. 2010;106(1):1-6.
5. Darke S, Kaye S, Duflou J. Systemic disease among cases of fatal opioid toxicity. Addiction. 2006;101(9):1299-1305.
6. Hulse G, White J, Cape G, editors. Management of Drug and Alcohol Problems. Sydney: Oxford University Press; 2002.
7. Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777-786.
8. McLaughlin PJ, Zagon IS, White WJ. Perinatal methadone exposure in rats. Effects on body and organ development. Biol Neonate. 1978;34(1-2):48-54.
9. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev. 2002;38(3): 351-376.
10. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p16INK4a and p21 WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell. 2009;20(1):319-327.
11. Feero WG, Guttmacher AE, McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010;363(24):2339-2350.
12. O'Donnell CJ, Nabel EG. Genomics of cardiovascular disease. N Engl J Med. 2011;365(22):2098-2109.
13. Visel A, Zhu Y, May D, et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature. 2010; 464(7287):409-412.
14. Harismendy O, Notani D, Song X, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature. 2011;470(7333):264-268.
15. Pasmant E, Sabbagh A, Vidaud M, Bieche I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 2010;25(2): 444-448.
16. Jamison RN, Serraillier J, Michna E. Assessment and treatment of abuse risk in opioid prescribing for chronic pain. Pain Res Treat. 2011;2011:941808.
17. US Department of Health and Human Services, Substance Abuse And Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network (DAWN), Treatment Episode Data Set-Admissions (Teds-A)-Concatenated, 1992 to 2009 [Computer file]. Prepared by Synectics for Management Decisions, Incorporated. ICPSR25221-v4. 2011;1. Available from http://www.samhsa.gov/data/DASIS.aspx?qr=t#TEDS. Accessed December 28, 2011.
18. Verbeke F, Marechal C, Van Laecke S, et al. Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. Hypertension. 2011;58(5):833-838.
19. Van Bortel LM, Duprez D, Starmans-Kool MJ, et al. Clinical applications of arterial stiffness, Task Force III: recommendations for user procedures. Am J Hypertens. 2002;15(5):445-452.
20. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens. 2005;18(1 Pt 2): 3S-10S.
21. Nichols WW. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. Nichols WW, O'Rourke MF, editors. London: Hodder Arnold; 2005.
22. Chien KR, Karsenty G. Longevity and lineages: toward the integrative biology of degenerative diseases in heart, muscle, and bone. Cell. 2005;120(4):533-544.
23. Opiate exposure increases arterial stiffness, advances vascular age and is an independent cardiovascular risk ractor in females: a cross-sectional clinical study. World J. Cardiovascular Diseases. In Press.
24. Reece AS, Hulse GK. Impact of opioid pharmacotherapy on arterial stiffness and vascular ageing: cross-sectional and longitudinal studies. Cardiovasc Toxicol. Epub March 3, 2013.
25. Reece AS, Hulse GK. Reduction in arterial stiffness and vascular age by naltrexone-induced interruption of opiate agonism. BMJ Open. 2013;3(3):e002610.
26. Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy. 2007;2:35.
27. Reece AS. Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers. Immun Ageing. 2007;4:6.
28. Hser YI, Gelberg L, Hoffman V, Grella CE, McCarthy W, Anglin MD. Health conditions among aging narcotics addicts: medical examination results. J Behav Med. 2004;27(6):607-622.
29. Randall D, Degenhardt L, Vajdic CM, et al. Increasing cancer mortality among opioid-dependent persons in Australia: a new public health challenge for a disadvantaged population. Aust N Z J Public Health. 2011;35(3):220-225.
30. Reece AS. Hypothalamic opioid-melanocortin appetitive balance and addictive craving. Med Hypotheses. 2011;76(1):132-137.
31. Rosen D, Smith ML, Reynolds CF 3rd. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatry. 2008;16(6):488-497.
32. Sadeghian S, Darvish S, Davoodi G, et al. The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2007; 14(5):715-717.
33. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009; 105(1-2):9-15.
34. Reece AS, Davidson P. Deficit of circulating stem-progenitor cells in opiate addiction: a pilot study. Subst Abuse Treat Prev Policy. 2007;2:19.
35. Russo SJ, Bolanos CA, Theobald DE, et al. IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates. Nat Neurosci. 2007;10(1):93-99.
36. Coppe JP, Rodier F, Patil CK, Freund A, Desprez PY, Campisi J. Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem. 2011;286(42):36396-36403.
37. Cunha-Oliveira T, Rego AC, Garrido J, Borges F, Macedo T, Oliveira CR. Street heroin induces mitochondrial dysfunction and apoptosis in rat cortical neurons. J Neurochem. 2007;101(2):543-554.
38. Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24(1):83-95.
39. Anderson JE. A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell. 2000;11(5): 1859-1874.
40. Bhaumik D, Scott GK, Schokrpur S, et al. MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging (Albany NY). 2009;1(4):402-411.
41. Reece AS. Dentition of addiction in Queensland: poor dental status and major contributing drugs. Aust Dent J. 2007;52(2):144-149.
42. Reece AS. Hair graying in substance addiction. Arch Dermatol. 2007;143(1):116-118.
43. Kim TW, Alford DP, Malabanan A, Holick MF, Samet JH. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend. 2006;85(3):258-262.